Pathologie et biologie des GIST (notice n° 1824701)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02588cam a2200265 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20260329003440.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Ngo, Carine |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Pathologie et biologie des GIST |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2026.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 85 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Les tumeurs stromales gastro-intestinales (GIST) sont les tumeurs mésenchymateuses les plus fréquentes du tube digestif et résultent le plus souvent de mutations activatrices des gènes KIT ou PDGFRA. Leur diagnostic repose sur la morphologie et l’immunohistochimie, avec une expression caractéristique de KIT (CD117) et DOG1. Les inhibiteurs de tyrosine kinase (ITK) (notamment l’imatinib) ont révolutionné leur prise en charge, améliorant nettement la survie des patients. Les formes dites « sauvages », sans mutation de KIT ou PDGFRA, regroupent des sous-types distincts, notamment les GIST déficientes en SDH et celles présentant des altérations de BRAF, NF1 ou NTRK.L’identification du profil moléculaire des GIST constitue une étape déterminante pour une prise en charge optimale, car le choix du type et la posologie du traitement par ITK dépendent directement du statut mutationnel tumoral. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the digestive tract and most often result from activating mutations in the KIT or PDGFRA genes. Their diagnosis relies on morphology and immunohistochemistry, with characteristic expression of KIT (CD117) and DOG1. Tyrosine kinase inhibitors (TKI), particularly imatinib, have revolutionized GIST management, significantly improving patient survival. The “wild-type” GISTs, lacking KIT or PDGFRA mutations, comprise distinct subtypes, including SDH-deficient GISTs and those harboring BRAF, NF1, or NTRK alterations.The identification of the molecular profile of GIST is a critical step for optimal patient management, as both the choice of TKI and its dosing directly depend on the tumor mutational status. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | inhibiteur de tyrosine kinase |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | mutations de KIT/PDGFRA |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | test moléculaire |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | tumeur stromale gastro-intestinale (GIST) |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | gastrointestinal stromal tumor (GIST) |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | KIT/PDGFRA mutations |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | molecular testing |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | tyrosine kinase inhibitor |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hépato-Gastro & Oncologie Digestive | 33 | N° Supp 1 | 2026-02-23 | p. 7-15 | 2115-3310 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://stm.cairn.info/revue-hepato-gastro-oncologie-digestive-2026-HS1-page-7?lang=fr&redirect-ssocas=7080">https://stm.cairn.info/revue-hepato-gastro-oncologie-digestive-2026-HS1-page-7?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux